Despite a challenging year with a stock price drop of over 41%, ACADIA Pharmaceuticals is seen by InvestingPro and Wall Street analysts as undervalued, with expectations of significant upside potential.
This equilibrium provides investors with a rare mix of potential for growth and relative stability - a combination hard to find in the more extreme ends of the market cap spectrum. The EPS Forecast Trend for Cable One for the upcoming first quarter of 2024, which is set for May 2, shows that analysts have revised their EPS expectations downward by 29.4% over the last 12 months, from $15.23 per share to $10.75 per share.Earlier this month, MoffettNathanson upgraded Cable One from Neutral to Buy, despite reducing its price target from $835 to $615. The firm highlighted challenges, particularly Cable One's broadband pricing strategy, crucial for its growth.
Despite these issues, MoffettNathanson believes “Cable One’s valuation is simply too low, and its assets too attractive, for it to remain at this price".assessment also indicates that the stock is currently undervalued, with investment models predicting a potential 36.9% increase in the stock price.Be sure to check out InvestingPro to stay in sync with the market trend and what it means for your trading.
Finance Finance Latest News, Finance Finance Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »